GlassScriptPhysician profile
Matthew A Brumbaugh
NPI 1346478534
$529.04
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $63.00 · 2021: $88.61.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $108.13 | 2019-2020 | |
| Boston Scientific Corporation | $100.00 | 2019 | |
| Amarin Pharma, INC. | $41.10 | 2019-2020 | |
| Novo Nordisk INC | $38.40 | 2019-2021 | |
| Pfizer INC. | $35.08 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $30.13 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $25.32 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $18.17 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.96 | 2021 | |
| Glaxosmithkline, LLC. | $16.56 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.05 | 2019 | |
| Sanofi Pasteur INC. | $14.93 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.85 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.57 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.80 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13.11 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Brumbaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.